433 related articles for article (PubMed ID: 24452484)
21. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management.
Rodríguez-Cerdeira C; González-Cespón JL; Martínez-Herrera E; Carnero-Gregorio M; López-Barcenas A; Sergeev A; Saunte DM
Ital J Dermatol Venerol; 2021 Oct; 156(5):545-557. PubMed ID: 33026212
[TBL] [Abstract][Full Text] [Related]
22. Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F.
Adams R; Maroof A; Baker T; Lawson ADG; Oliver R; Paveley R; Rapecki S; Shaw S; Vajjah P; West S; Griffiths M
Front Immunol; 2020; 11():1894. PubMed ID: 32973785
[TBL] [Abstract][Full Text] [Related]
23. Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease.
Reich K; Warren RB; Coates LC; Di Comite G
J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1161-1173. PubMed ID: 31785165
[TBL] [Abstract][Full Text] [Related]
24. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
Vu TT; Gooderham M; Papp K
Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
[TBL] [Abstract][Full Text] [Related]
25. Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.
Canavan TN; Elmets CA; Cantrell WL; Evans JM; Elewski BE
Am J Clin Dermatol; 2016 Feb; 17(1):33-47. PubMed ID: 26649440
[TBL] [Abstract][Full Text] [Related]
26. Secukinumab for treating plaque psoriasis.
Rothstein B; Gottlieb A
Expert Opin Biol Ther; 2016; 16(1):119-28. PubMed ID: 26577956
[TBL] [Abstract][Full Text] [Related]
27. Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.
Gottlieb AB; Langley RG; Philipp S; Sigurgeirsson B; Blauvelt A; Martin R; Papavassilis C; Mpofu S
J Drugs Dermatol; 2015 Aug; 14(8):821-33. PubMed ID: 26267726
[TBL] [Abstract][Full Text] [Related]
28. Secukinumab for rheumatology: development and its potential place in therapy.
Koenders MI; van den Berg WB
Drug Des Devel Ther; 2016; 10():2069-80. PubMed ID: 27445458
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis.
Mease PJ
Curr Opin Rheumatol; 2015 Mar; 27(2):127-33. PubMed ID: 25599143
[TBL] [Abstract][Full Text] [Related]
30. New therapies for psoriasis and psoriatic arthritis.
Ritchlin CT; Krueger JG
Curr Opin Rheumatol; 2016 May; 28(3):204-10. PubMed ID: 27022911
[TBL] [Abstract][Full Text] [Related]
31. The plot thickens while the scope broadens: a holistic view on IL-17 in psoriasis and other inflammatory disorders.
Schön MP
Exp Dermatol; 2014 Nov; 23(11):804-6. PubMed ID: 25219805
[TBL] [Abstract][Full Text] [Related]
32. β-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis.
Kolbinger F; Loesche C; Valentin MA; Jiang X; Cheng Y; Jarvis P; Peters T; Calonder C; Bruin G; Polus F; Aigner B; Lee DM; Bodenlenz M; Sinner F; Pieber TR; Patel DD
J Allergy Clin Immunol; 2017 Mar; 139(3):923-932.e8. PubMed ID: 27502297
[TBL] [Abstract][Full Text] [Related]
33. IL-17 for therapy.
Kurschus FC; Moos S
J Dermatol Sci; 2017 Sep; 87(3):221-227. PubMed ID: 28633806
[TBL] [Abstract][Full Text] [Related]
34. Ixekizumab for the treatment of psoriasis: an update on new data since first approval.
Blegvad C; Skov L; Zachariae C
Expert Rev Clin Immunol; 2019 Feb; 15(2):111-121. PubMed ID: 30589394
[No Abstract] [Full Text] [Related]
35. Anti-IL17 therapies for psoriasis.
Silfvast-Kaiser A; Paek SY; Menter A
Expert Opin Biol Ther; 2019 Jan; 19(1):45-54. PubMed ID: 30500317
[TBL] [Abstract][Full Text] [Related]
36. Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis.
Toussirot E
Expert Opin Biol Ther; 2018 Jan; 18(1):101-107. PubMed ID: 29187009
[TBL] [Abstract][Full Text] [Related]
37. Psoriasis and other Th17-mediated skin diseases.
Tokura Y; Mori T; Hino R
J UOEH; 2010 Dec; 32(4):317-28. PubMed ID: 21226422
[TBL] [Abstract][Full Text] [Related]
38. Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab.
Hanley TL; Yiu ZZ
Ther Clin Risk Manag; 2017; 13():315-323. PubMed ID: 28352182
[TBL] [Abstract][Full Text] [Related]
39. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.
Reich K; Blauvelt A; Armstrong A; Langley RG; Fox T; Huang J; Papavassilis C; Liang E; Lloyd P; Bruin G
Br J Dermatol; 2017 Mar; 176(3):752-758. PubMed ID: 27518376
[TBL] [Abstract][Full Text] [Related]
40. Interleukin (IL)-17/IL-36 axis participates to the crosstalk between endothelial cells and keratinocytes during inflammatory skin responses.
Mercurio L; Failla CM; Capriotti L; Scarponi C; Facchiano F; Morelli M; Rossi S; Pagnanelli G; Albanesi C; Cavani A; Madonna S
PLoS One; 2020; 15(4):e0222969. PubMed ID: 32352958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
